A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

• Status: Completed
• Trial end date: 2017-01-04
• Target enrollment: 0
• Participant gender: All

Summary

This study will compare the efficacy, in terms of complete responses and overall survival, of inotuzumab ozogamicin versus investigator's choice of chemotherapy.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Collaborator: UCB Pharma
• Treatments: Cytarabine; Fludarabine; Fludarabine phosphate; Inotuzumab Ozogamicin; Mitoxantrone

Criteria

Inclusion Criteria:

• CD22 expression

• Adequate liver and renal functions

Exclusion Criteria:

• Isolated extramedullary disease

• Active Central Nervous System [CNS] disease